While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss ...

Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.

This pushed Lilly to raise its sales outlook for the year by $2 billion, despite short revenue from diabetes treatments Mounjaro and Trulicity. Analysts noted Eli Lilly and its biggest rival ...

Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. Following our analysis of the options activities associated with Eli Lilly, we pivot to a closer look at ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Exxon Mobil ...

Billionaire investor Ray Dalio says dollar bulls should worry about crypto.

Wedge Capital Management L L P NC decreased its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 26.0% ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

Equities researchers at Leerink Partnrs decreased their FY2024 earnings per share estimates for shares of Eli Lilly and ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity ...